Trial Profile

Phase 2 clinical trial evaluating the efficacy and safety of ART-001 in patients with slow-flow vascular malformations

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ART-001 (Primary)
Indications Lymphangioma; Vascular malformations
Focus Therapeutic Use

Most Recent Events

11 Oct 2024 Status changed to active, no longer recruiting.
03 Feb 2023 According to an ARTham Therapeutics media release, results from this trial were presented at International Conference on Vascular Anomalies 2023 (VAC2023).
03 Feb 2023 Primary endpoint (Proportion of subjects with response defined by MRI volumetric change of target lesion at Week 24.) has been met, according to a Kaken Pharmaceutical media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com